The platelet to lymphocyte ratio (PLR) has recently emerged as a potential inflammatory biomarker. Hence, we assessed the relationship between PLR and the extent/severity of coronary artery disease (CAD) using the Gensini score in association with the inflammatory marker C-reactive protein (CRP) in patients with stable CAD. Angiographic data of 1646 patients were analyzed in this cross-sectional study. Patients were categorized according to Gensini scores as no CAD (control), mild, and severe CAD groups. The PLR in the control group was significantly lower than those of mild and severe CAD groups. In multivariate logistic regression analysis, PLR was found to be an independent predictor of the presence of severe CAD (odds ratio: 1.043 [1.036-1.049], P < .001). Furthermore, there was a significant correlation between PLR and the severity of CAD (r = .370, P < .001) and CRP levels (r = .312, P < .001). In conclusion, PLR was independently and positively associated with the severity of coronary atherosclerosis. These results suggest that PLR is an easily available and cheap inflammatory indicator that can be used in predicting the severity of CAD.
LibbyP. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–874.
2.
DrakopoulouMToutouzasKStefanadiETsiamisETousoulisDStefanadisC. Association of inflammatory markers with angiographic severity and extent of coronary artery disease. Atherosclerosis. 2009;206(2):335–339.
3.
TurfanMDuranMPoyrazF. Inverse relationship between serum total bilirubin levels and severity of disease in patients with stable coronary artery disease. Coron Artery Dis. 2013;24(1):29–32.
4.
LyHQKirtaneAJMurphySA. Association of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials). Am J Cardiol. 2006;98(1):1–5.
5.
IijimaRNdrepepaGMehilliJ. Relationship between platelet count and 30 day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials. Thromb Haemost. 2007;98(4):852–857.
6.
NikolskyEGrinesCLCoxDA. Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial). Am J Cardiol. 2007;99(8):1055–1061.
7.
OmmenSRGibbonsRJHodgeDOThomsonSP. Usefulness of the lymphocyte concentration as a prognostic marker in coronary artery disease. Am J Cardiol. 1997;79(6):812–814.
8.
ZouridakisEGGarcia-MollXKaskiJC. Usefulness of the blood lymphocyte count in predicting recurrent instability and death in patients with unstable angina pectoris. Am J Cardiol. 2000;86(4):449–451.
9.
ProctorMJMorrisonDSTalwarD. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow inflammation outcome study. Eur J Cancer. 2011;47(17):2633–2641.
10.
KoseogluHIAltunkasFKanbayADorukSEtikanIDemirO. Platelet-lymphocyte ratio is an independent predictor for cardiovascular disease in obstructive sleep apnea syndrome. J Thromb Thrombolysis. 2015;39(2):179–185.
11.
GaryTPichlerMBelajK. Platelet-to-lymphocyte ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients. PLoS One. 2013;8(7):e67688.
12.
AzabBShahNAkermanMMcGinnJTJr. Value of platelet/ lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction. J Thromb Thrombolysis. 2012;34(3):326–334.
13.
UgurMGulMBozbayM. The relationship between platelet to lymphocyte ratio and the clinical outcomes in ST elevation myocardial infarction underwent primary coronary intervention. Blood Coagul Fibrinolysis. 2014;25(8):806–811.
14.
YükselMYıldızAOylumluM. The association between platelet/lymphocyte ratio and coronary artery disease severity. Anadolu Kardiyol Derg. 2014. doi:10.5152/akd.2014.5565.
15.
FihnSDGardinJMAbramsJ. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2012;60(24):e44–e164.
16.
GensiniGG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51(3):606.
17.
AkbogaMKCanpolatUSahinarslanA. Association of serum total bilirubin level with severity of coronary atherosclerosis is linked to systemic inflammation. Atherosclerosis. 2015;240(1):110–114.
18.
HanssonGK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–1695.
19.
LindemannSKramerBSeizerPGawazM. Platelets, inflammation and atherosclerosis. J Thromb Haemost. 2007;5(suppl 1):203–211.
20.
GawazMLangerHMayAE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115(12):3378–3384.
21.
ThaulowEErikssenJSandvikLStormorkenHCohnPF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation. 1991;84(2):613–617.
22.
HorneBDAndersonJLJohnJM; Intermountain Heart Collaborative Study Group. Which white blood cell subtypes predict increased cardiovascular risk?J Am Coll Cardiol. 2005;45(10):1638–1643.
23.
ThomsonSPMcMahonLJNugentCA. Endogenous cortisol: a regulator of the number of lymphocytes in peripheral blood. Clin Immunol Immunopathol. 1980;17(4):506–514.
24.
AkbogaMKCanpolatUBalciK. Increased platelet to lymphocyte ratio is related to slow coronary flow. Angiology. 2015. doi: 10.1177/0003319715574625.
25.
YaylaCAkbogaMKCanpolatU. Platelet to lymphocyte ratio can be a predictor of infarct-related artery patency in patients with ST-segment elevation myocardial infarction. Angiology. 2015. doi: 10.1177/0003319715573658.
26.
SunbulMGerinFDurmusE. Neutrophil to lymphocyte and platelet to lymphocyte ratio in patients with dipper versus non-dipper hypertension. Clin Exp Hypertens. 2014;36(4):217–221.
27.
MunkPSBrelandUMAukrustPSkadbergOUelandTLarsenAI. Inflammatory response to percutaneous coronary intervention in stable coronary artery disease. J Thromb Thrombolysis. 2011;31(1):92–98.
28.
KoenigWSundMFröhlichM. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99(2):237–242.
29.
KullerLHTracyRPShatenJMeilahnEN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996;144(6):537–547.
30.
RayKKNazerBCairnsRMichael GibsonCCannonCP. Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes. J Thromb Thrombolysis. 2010;30(1):10–13.
31.
DaneshJWheelerJGHirschfieldGM. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):1387–1397.
32.
HarrisTBFerrucciLTracyRP. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106(5):506–512.
33.
MorrowDAde LemosJASabatineMS. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 2006;114(4):281–288.
34.
CicekGAcıkgozSKBozbayM. Neutrophil-Lymphocyte ratio and platelet-lymphocyte ratio combination can predict prognosis in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Angiology. 2014. doi: 10.1177/0003319714535970.
35.
BaltaSDemirkolSArslanZCelikTUnluMIyisoyA. Retinal vessel abnormalities and coronary artery diseases. Perfusion. 2013;28(5):465.
36.
BaltaSOzturkC. The platelet–lymphocyte ratio: A simple, inexpensive and rapid prognostic marker for cardiovascular events. Platelets. 2014;30:1–2.
